目的 評價鹽酸安非他酮緩釋片治療抑郁癥的療效和安全性。
方法 采用隨機(jī)雙盲雙模擬方法，將符合CCMD-3有關(guān)單相抑郁發(fā)作和雙相情感障礙抑郁發(fā)作標(biāo)準(zhǔn)的患者48例，隨機(jī)分為安非他酮組和氟西汀組。兩組患者于清洗3~7天后分別給予鹽酸安非他酮緩釋片300 mg/d和氟西汀片20 mg/d，療程均為42天。臨床療效觀察采用漢密爾頓抑郁量表（HAMD）評分、漢密爾頓焦慮量表（HAMA）評分、臨床總體印象量表（CGI）評分和治療藥物副作用量表（TESS），實驗室檢查包括血常規(guī)、小便常規(guī)、生化和心電圖。
結(jié)果 兩組基線與治療各階段HAMD量表、HAMA量表評分的變化情況顯示：安非他酮組治療有效率83.3%（20/ 24），氟西汀組為62.5%（15/24）；兩組不良反應(yīng)率均為45.9%（11/24），未見嚴(yán)重不良反應(yīng)。
結(jié)論 安非他酮和氟西汀組療效相當(dāng)，能有效治療抑郁癥及伴隨焦慮癥狀，不良反應(yīng)輕微。
引用本文： 王雪,張波,李靜,孫學(xué)禮. 鹽酸安非他酮緩釋片治療抑郁癥的雙盲雙模擬隨機(jī)對照試驗. 中國循證醫(yī)學(xué)雜志, 2007, 07(6): 409-414. doi: 復(fù)制
版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國循證醫(yī)學(xué)雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
| 1. | Tomarken AJ, Dichter GS, Freid C, et al. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord, 2004, 78(3): 235-241. |
| 2. | Glod CA, Lynch A, Flynn E, et al. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs, 2003, 16(3): 123-130. |
| 3. | Jamerson BD, Krishnan KR, Roberts J, et al. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol Bull, 2003, 37(2): 67-78. |
| 4. | Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther, 2002, 24(4): 662-672. |
| 5. | Weihs KL, Houser TL, Batey S R, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry, 2002, 51(9): 753-761. |
| 6. | Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother, 2001, 35(12): 1608-1613. |
| 7. | Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry, 2001, 16(9): 862-865. |
| 8. | Weihs KL, Sette EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry, 2000, 61(3): 196-202. |
| 9. | Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry, 2001, 40(3): 307-314. |
| 10. | Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion. Ned Tijdschr Geneeskd, 2000, 144(45): 2157-2159. |
| 11. | Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother, 1999, 33(6): 701-703. |
| 12. | Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol,1996, 16(1): 80-81. |
| 13. | Apter JT, Kushner SF, Woolfolk RL. Bupropion/nortriptyline combination for refractory depression. Ann Clin Psychiatry, 1994, 6(4): 255-258. |
| 14. | Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther, 1999, 21(3): 454-463. |
- 1. Tomarken AJ, Dichter GS, Freid C, et al. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord, 2004, 78(3): 235-241.
- 2. Glod CA, Lynch A, Flynn E, et al. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs, 2003, 16(3): 123-130.
- 3. Jamerson BD, Krishnan KR, Roberts J, et al. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol Bull, 2003, 37(2): 67-78.
- 4. Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther, 2002, 24(4): 662-672.
- 5. Weihs KL, Houser TL, Batey S R, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry, 2002, 51(9): 753-761.
- 6. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother, 2001, 35(12): 1608-1613.
- 7. Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry, 2001, 16(9): 862-865.
- 8. Weihs KL, Sette EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry, 2000, 61(3): 196-202.
- 9. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry, 2001, 40(3): 307-314.
- 10. Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion. Ned Tijdschr Geneeskd, 2000, 144(45): 2157-2159.
- 11. Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother, 1999, 33(6): 701-703.
- 12. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol,1996, 16(1): 80-81.
- 13. Apter JT, Kushner SF, Woolfolk RL. Bupropion/nortriptyline combination for refractory depression. Ann Clin Psychiatry, 1994, 6(4): 255-258.
- 14. Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther, 1999, 21(3): 454-463.